Nzeera Ketter - Concepedia

Author

Nzeera Ketter

Janssen (United States)

Also Known As

N Ketter, N. KETTER, N. Ketter, Nzeera Ketter, Nzeera Ketter (62307)

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Johnson & Johnson (United States)Pfizer (United States)International AIDS Vaccine Initiative National Institute of Allergy and Infectious Diseases

About

Nzeera Ketter is an author at Janssen (United States) specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	229
2	Immunology	4	4	158
3	Neurology	3	3	73
4	Hospital Medicine	1	1	41
5	Pathology	1	1	48

Nzeera Ketter

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease Stephen Salloway, Reisa A. Sperling, Nick C. Fox, New England Journal of Medicine	2014	1.9K
Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection Jeffrey M. Jacobson, John S. Greenspan, John Spritzler, New England Journal of Medicine	1997	422
A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection Robert R. Redfield, Deborah L. Birx, Nzeera Ketter, New England Journal of Medicine	1991	245
CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa Etienne Karita, Nzeera Ketter, Matt A. Price, PLoS ONE	2009	165
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study Álvaro Réa-Neto, Michael S. Niederman, Suzana Margareth Lobo, Current Medical Research and Opinion	2008	119
Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa Etienne Karita, Matt A. Price, Eric Hunter, AIDS	2007	114
Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease Florence Pasquier, Carl Sadowsky, Ann R Holstein, Journal of Alzheimer s Disease	2016	101
Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients Nzeera Ketter, H. Robert Brashear, Jennifer Bogert, Journal of Alzheimer s Disease	2017	82
A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide Vaccine Geoffrey J. Gorse, M. C. Keefer, Robert B. Belshe, The Journal of Infectious Diseases VaccinationMn StrainVaccine DevelopmentVaccine ResearchPrototype Vaccine	1996	67
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis H. Michael Arrighi, Jerome Barakos, Frederik Barkhof, Journal of Neurology Neurosurgery & Psychiatry	2015	61

Page 1